Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Novel DOX-MTX Nanoparticles Improve Oral SCC Clinical Outcome by Down Regulation of Lymph Dissemination Factor VEGF-C Expression in vivo: Oral and IV Modalities

  • Abbasi, Mehran Mesgari (Drug Applied Research Center, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) ;
  • Monfaredan, Amir (Department of Hematology, Faculty of Medicine, Islamic Azad University) ;
  • Hamishehkar, Hamed (Drug Applied Research Center, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) ;
  • Seidi, Khaled (Department of Medical Biotechnologies, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences) ;
  • Jahanban-Esfahlan, Rana (Student Research Committee, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Oral squamous cell carcinoma (OSCC) remains as one of the most difficult malignancies to control because of its high propensity for local invasion and cervical lymph node dissemination. The aim of present study was to evaluate the efficacy of novel pH and temperature sensitive doxorubicin-methotrexate-loaded nanoparticles (DOX-MTX NP) in terms of their potential to change the VEGF-C expression profile in a rat OSCC model. Materials and Methods: 120 male rats were divided into 8 groups of 15 animals administrated with 4-nitroquinoline-1-oxide to induce OSCCs. Newly formulated doxorubicin-methotrexate-loaded nanoparticles (DOX-MTX NP) and free doxorubicin were IV and orally administered. Results: Results indicated that both oral and IV forms of DOX-MTX-nanoparticle complexes caused significant decrease in the mRNA level of VEGF-C compared to untreated cancerous rats (p<0.05). Surprisingly, the VEGF-C mRNA was not affected by free DOX in both IV and oral modalities (p>0.05). Furthermore, in DOX-MTX NP treated group, less tumors characterized with advanced stage and VEGF-C mRNA level paralleled with improved clinical outcome (p<0.05). In addition, compared to untreated healthy rats, the VEGF-C expression was not affected in healthy groups that were treated with IV and oral dosages of nanodrug (p>0.05). Conclusions: VEGF-C is one of the main prognosticators for lymph node metastasis in OSCC. Down-regulation of this lymph-angiogenesis promoting factor is a new feature acquired in group treated with dual action DOX-MTX-NPs. Beside the synergic apoptotic properties of concomitant use of DOX and MTX on OSCC, DOX-MTX NPs possessed anti-angiogenesis properties which was related to the improved clinical outcome in treated rats. Taking together, we conclude that our multifunctional doxorubicin-methotrexate complex exerts specific potent apoptotic and anti-angiogenesis properties that could ameliorate the clinical outcome presumably via down-regulating dissemination factor-VEGF-C expression in a rat OSCC model.

Keywords

References

  1. Albano PM, Lumang-Salvador C, Orosa J 3rd , et al (2013). Overall survival of Filipino patients with squamous cell carcinoma of the head and neck: a single-institution experience. Asian Pac J Cancer Prev, 14, 4769-74. https://doi.org/10.7314/APJCP.2013.14.8.4769
  2. Baykara M, Buyukberber S, Ozturk B, et al (2013). Efficacy and safety of concomitant chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced squamous cell head and neck cancers. Asian Pac J Cancer Prev, 14, 2557-61. https://doi.org/10.7314/APJCP.2013.14.4.2557
  3. Bell RB, Kademani D, Homer L, Dierks EJ, Potter BE (2007). Tongue cancer: Is there a difference in survival compared with other subsites in the oral cavity? J Oral Maxillofac Surg, 65, 229-236. https://doi.org/10.1016/j.joms.2005.11.094
  4. Bell RB, Kademani D, Homer L, Dierks EJ , Potter BE (2007). Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability. Int J Pharm, 423, 554-561.
  5. Chen Y, Wan Y, Wang Y, Zhang H , Jiao Z (2011). Anticancer efficacy enhancement and attenuation of side effects of doxorubicin with titanium dioxide nanoparticles. Int J Nanomedicine, 6, 2321-26.
  6. Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R (2014). Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. current and emerging paradigms. Clin Ther, 36, 427-35. https://doi.org/10.1016/j.clinthera.2014.01.014
  7. Colleoni M, Rocca A, Sandri MT, et al (2002). Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol, 13, 73-80.
  8. Deng Y, Zhang H (2013). The synergistic effect and mechanism of doxorubicin-ZnO nanocomplexes as a multimodal agent integrating diverse anticancer therapeutics. Int J Nanomedicine, 8, 1835-41.
  9. Duong HH, Yung LY (2013). Synergistic co-delivery of doxorubicin and paclitaxel using multi-functional micelles for cancer treatment. Int J Pharm, 454, 489-95
  10. Gibson RJ, Bowen JM, Cummins AG , Keefe DM (2005). Relationship between dose of methotrexate, apoptosis, p53/p21 expression and intestinal crypt proliferation in the rat. Clin Exp Med, 4, 188-95. https://doi.org/10.1007/s10238-004-0055-y
  11. Han W, Yang X, Huang X, Hu Q , Wang Z (2008). Metastases to lingual lymph nodes from squamous cell carcinoma of the tongue. Br J Oral Maxillofac Surg, 46, 376-78. https://doi.org/10.1016/j.bjoms.2007.12.002
  12. Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K (1989). Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum, 32, 1065-73. https://doi.org/10.1002/anr.1780320903
  13. Hu CM, Aryal S, Zhang L (2010). Nanoparticle-assisted combination therapies for effective cancer treatment. Ther Deliv, 1, 323-34. https://doi.org/10.4155/tde.10.13
  14. Huang WY, Yang P M, Chang YF, Marquez VE, Chen CC (2011). Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol, 81, 510-17. https://doi.org/10.1016/j.bcp.2010.11.014
  15. Jahanban Esfahlan R, Zarghami N, Jahanban Esfahlan A, et al (2011). The possible impact of obesity on androgen, progesterone and estrogen receptors ($ER\alpha$ and $ER\beta$) Gene expression in breast cancer patients. Breast Cancer, 227-37.
  16. Jahanban Esfahlan R, Zarghami N, Rahmati-Yamchi M, et al (2011). Quantification of steroid receptors gene expression in breast cancer patients: possible correlation with serum level of adipocytokines. J Cancer Therapy, 2, 659-65. https://doi.org/10.4236/jct.2011.25088
  17. Jahanban Esfahlan R, Zarghami N, Valiyari S, et al (2012). Adiponectin can affect ER signaling in obese breast cancer patients. J Cancer Therapy, 3, 115-21 https://doi.org/10.4236/jct.2012.31015
  18. Jones KR, Lodge-Rigal RD, Reddick RL, Tudor GE , Shockley WW (1992). Prognostic factors in the recurrence of stage I and II squamous cell cancer of the oral cavity. Arch Otolaryngol Head Neck Surg, 118, 483-5. https://doi.org/10.1001/archotol.1992.01880050029006
  19. Kademani D, Bell RB, Bagheri S, et al (2005). Prognostic factors in intraoral squamous cell carcinoma: the influence of histologic grade. J Oral Maxillofac Surg, 63, 1599-605. https://doi.org/10.1016/j.joms.2005.07.011
  20. Kalaria DR, Sharma G, Beniwal V, Ravi Kumar MN (2009). Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm.Res., 26, 492-501. https://doi.org/10.1007/s11095-008-9763-4
  21. Lasrado S, Moras K, Pinto GJ ,et al. (2014). Role of concomitant chemoradiation in locally advanced head and neck cancers. Asian Pac J Cancer Prev, 15, 4147-52. https://doi.org/10.7314/APJCP.2014.15.10.4147
  22. Liboiron BD, Mayer LD (2014). Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy. Ther Deliv, 5, 149-71. https://doi.org/10.4155/tde.13.149
  23. Liu F, Tan G, Li J, et al (2007). Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice. Cancer Sci, 98, 1381-7. https://doi.org/10.1111/j.1349-7006.2007.00542.x
  24. Liu F, Wang P, Jiang X, et al (2008). Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci, 99, 2055-61.
  25. Massano J, Regateiro FS, Januario G , Ferreira A (2006). Oral squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 102, 67-76. https://doi.org/10.1016/j.tripleo.2005.07.038
  26. Mehdipour M, Taghavi ZA, Mesgari AM, et al (2013). Evaluation of the effect of two systemic doses of HESA-A on prevention of induced tongue neoplasm in rats. J Dent Res Dent Clin Dent Prospects, 7, 218-24.
  27. Mohamed KM, Le A, Duong H, et al (2004). Correlation between VEGF and HIF-1alpha expression in human oral squamous cell carcinoma. Exp Mol Pathol, 76, 143-52. https://doi.org/10.1016/j.yexmp.2003.10.005
  28. Mollazade M, Nejati-Koshki K, Akbarzadeh A, et al (2013). PAMAM dendrimers augment inhibitory effects of curcumin on cancer cell proliferation: possible inhibition of telomerase. Asian Pac J Cancer Prev, 14, 6925-28. https://doi.org/10.7314/APJCP.2013.14.11.6925
  29. Montoro JR, Ricz HA, Souza L, et al (2008). Prognostic factors in squamous cell carcinoma of the oral cavity. Braz J Otorhinolaryngol, 74, 861-6.
  30. Nasiri M, Nejati NZ, Koshki K, et al (2013). Curcumin and silibinin inhibit telomerase expression in T47D human breast cancer cells. Asian Pacific J Cancer Prev, 14, 3449-3453. https://doi.org/10.7314/APJCP.2013.14.6.3449
  31. Park SK, Kim HI, Yang YI, Hur DY (2011). Effects of methotrexate on vascular endothelial growth factor, angiopoietin 1, and angiopoietin 2 in nasal polyps. Am J Rhinol Allergy, 25, e129-e32. https://doi.org/10.2500/ajra.2011.25.3618
  32. Rossi B, Schinzari G, Maccauro G, et al (2010). Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. BMC Musculoskelet Disord, 11, 34. https://doi.org/10.1186/1471-2474-11-34
  33. Rusthoven KE, Raben D, Song JI, et al (2010). Survival and patterns of relapse in patients with oral tongue cancer. J.Oral Maxillofac.Surg., 68, 584-589. https://doi.org/10.1016/j.joms.2009.03.056
  34. Salehi R, Hamishehkar H, Eskandani M, Mahkam M , Davaran S (2014). Development of dual responsive nanocomposite for simultaneous delivery of anticancer drugs. J Drug Target, 22, 327-42. https://doi.org/10.3109/1061186X.2013.876645
  35. Schliephake H (2003). Prognostic relevance of molecular markers of oral cancer--a review. Int J Oral Maxillofac Surg, 32, 233-45. https://doi.org/10.1054/ijom.2002.0383
  36. Shaker OG, Khairallah M, Rasheed HM, et al (2013). Antiangiogenic effect of methotrexate and PUVA on psoriasis. Cell Biochem.Biophys, 67, 735-42.
  37. Shintani S, Li C, Ishikawa T, et al (2004). Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. Oral Oncol, 40, 13-20.
  38. Srivastava VK, Gara Rk Fau, Rastogi N, et al (2014). Serum vascular endothelial growth factor-A (VEGF-A) as a biomarker in squamous cell carcinoma of head and neck patients undergoing chemoradiotherapy. Asian Pac J Cancer Prev, 15, 3261-65. https://doi.org/10.7314/APJCP.2014.15.7.3261
  39. Sugiura T, Inoue Y, Matsuki R, et al (2009). VEGF-C and VEGF-D expression is correlated with lymphatic vessel density and lymph node metastasis in oral squamous cell carcinoma: Implications for use as a prognostic marker. Int J Oncol, 34, 673-80.
  40. Tacar O, Sriamornsak P, Dass CR (2013). Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol, 65, 157-70. https://doi.org/10.1111/j.2042-7158.2012.01567.x
  41. Uehara M, Sano K, Ikeda H, et al (2004). Expression of vascular endothelial growth factor and prognosis of oral squamous cell carcinoma. Oral Oncol, 40, 321-32. https://doi.org/10.1016/j.oraloncology.2003.08.020
  42. Wang Y, Wei X, Zhang C, Zhang F, Liang W (2010). Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects. Ther Deliv, 1, 273-87. https://doi.org/10.4155/tde.10.24
  43. Zhao SF, Yang XD, Lu MX, et al (2013). Prognostic significance of VEGF immunohistochemical expression in oral cancer: a meta-analysis of the literature. Tumour Biol, 34, 3165-71. https://doi.org/10.1007/s13277-013-0886-9
  44. Zwetyenga N, Majoufre-Lefebvre C, Siberchicot F, Demeaux H, Insolle J (2003). Squamous-cell carcinoma of the tongue: treatment results and prognosis. Rev Stomatol Chir Maxillofac, 104, 10-17.

Cited by

  1. DOX-MTX-NPs Augment p53 mRNA Expression in OSCC Model in Rat: Effects of IV and Oral Routes vol.15, pp.19, 2014, https://doi.org/10.7314/APJCP.2014.15.19.8377
  2. New formulated "DOX-MTX-loaded Nanoparticles" Down-regulate HER2 Gene Expression and Improve the Clinical Outcome in OSCCs Model in Rat: the Effect of IV and Oral Modalities vol.15, pp.21, 2014, https://doi.org/10.7314/APJCP.2014.15.21.9355
  3. Decreased expression of carbonyl reductase 1 promotes ovarian cancer growth and proliferation vol.46, pp.3, 2015, https://doi.org/10.3892/ijo.2014.2810
  4. Oral and IV Dosages of Doxorubicin-Methotrexate loaded-Nanoparticles Inhibit Progression of Oral Cancer by Down-Regulation of Matrix Methaloproteinase 2 Expression in Vivo vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10705
  5. Hesa-A Improves Clinical Outcome of Oral Carcinoma by Affecting p53 Gene Expression in vivo vol.16, pp.10, 2015, https://doi.org/10.7314/APJCP.2015.16.10.4169
  6. Anti Tumoral Properties of Punica Granatum (Pomegranate) Peel Extract on Different Human Cancer Cells vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5697
  7. Anti Proliferative Properties of Melissa officinalis in Different Human Cancer Cells vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5703
  8. Hesa-A Down-Regulates erb/b2 Oncogene Expression and Improves Outcome of Oral Carcinoma in a Rat Model vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6947
  9. Anti-Proliferative Effects of Hesa-A on Human Cancer Cells with Different Metastatic Potential vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.6963
  10. Modulating tumor hypoxia by nanomedicine for effective cancer therapy vol.233, pp.3, 2017, https://doi.org/10.1002/jcp.25859
  11. Combination of nanotechnology with vascular targeting agents for effective cancer therapy vol.233, pp.4, 2017, https://doi.org/10.1002/jcp.26051